Open AccessP04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
Author(s) -
Sonneveld P,
ChananKhan A,
Weisel K,
Nooka AK,
Masszi T,
Beksac M,
Spicka I,
Hungria V,
Munder M,
Mateos MV,
Mark TM,
Levin MD,
Ahmadi T,
Qin X,
Garvin Mayo W,
Gai X,
Carey J,
Carson R,
Spencer A
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000829588.31575.a9
Subject(s) - daratumumab , medicine , dexamethasone , bortezomib , multiple myeloma , clinical endpoint , oncology , randomized controlled trial